Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2931457

Cc1ccc(C(=O)N2CCN(C)CC2)cc1Nc1cncc(-c2ccc(O)cc2)n1.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FASN P49327 2/20 0.46
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SYK P43405 1/20 0.41
ATR Q13535 2/20 0.41
HDAC4 P56524 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
CHEK1 O14757 2/20 0.41
PIM3 Q86V86 1/20 0.40
KCNH2 Q12809 1/20 0.40
STAT3 P40763 1/20 0.40
CDK6 Q00534 2/20 0.39
GSK3B P49841 2/20 0.39
CCNE2 O96020 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13515277 0.94 FASN (0.50) FASNMKNK1MKNK2ATRCHEK1
Trifluoroacetic Acid SCHEMBL2935027 0.91 MKNK1 (0.41) MKNK1MKNK2L3MBTL1SYKATR
Trifluoroacetic Acid SCHEMBL2933929 0.89 PIM3 (0.51) MKNK1MKNK2L3MBTL1ATRHDAC4
SCHEMBL2931460 0.88 FASN (0.45) FASNMKNK1MKNK2SYKATR
SCHEMBL13515300 0.84 MKNK1 (0.46) FASNMKNK1MKNK2ATRCHEK1
SCHEMBL13515311 0.82 PIM3 (0.54) MKNK1MKNK2CHEK1PIM3KCNH2
SCHEMBL2932525 0.82 LRRK2 (0.46) MKNK1MKNK2ATRCHEK1CDK2
SCHEMBL2934437 0.81 TTK (0.52) PIM3DYRK1A
SCHEMBL2932403 0.79 PIM3 (0.53) CHEK1PIM3
SCHEMBL2935031 0.79 PIM3 (0.40) MKNK1MKNK2ATRHDAC4HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 FASN 4597/4885MKNK1 75/4885MKNK2 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.